Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.

Cheryl says, "It can be a killer if you take a high valuation and then the next round you have to do a down round. The whole psyche of your investors goes sour.”

Source

WSJ Pro Venture Capital